Blue Horseshoe Stocks: Options Review & More

Options Review

Bed Bath & Beyond, Inc. BBBY – Yesterday morning’s premarket report contained an options idea for Bed Bath & Beyond following the company’s quarterly earnings report, the BBBY Weekly $13 & $13.50 Calls, and those plays both turned in fantastic intraday performances.

Regardless of which strike point was chosen, traders could have secured multi-bag profits on the day. The $13 Calls traded up from a low of .30 to a high of 1.30, for an increase of 333%, while the $13.50′s also crushed it with a huge 431% rip from .16-.85!
_______

Constellation Brands Inc. STZ -Just as Constellation stock got crushed to new lows in the premarket on Wednesday, we formulated a couple of longer-term options ideas, and wanted to provide updates on the activity there as well.

We were banking on STZ reversing off of those lows and beginning a recovery, and so far, it’s going quite well. Our targets were the  the STZ 02/01 $150-157.50 Calls and the 04/18 $160-170 Calls, and all seven sets of contracts in those ranges have been good for significant gain opportunities. These remain in play, and will remain on our watchlist going forward.

02/01 $150-157.50 Calls
$150 Calls – Range: 8.80-11.50 – Max Gain: 31%
$152.50 Calls – Range: 3.80-6.70 – Max Gain: 76%
$155 Calls – Range: 2.90-8.00 – Max Gain: 176%
$157.50 Calls – Range: 3.00-6.65 – Max Gain: 122%

04/18 $160-170 Calls

$160 Calls – Range: 5.50-10.83 – Max Gain: 97%
$165 Calls – Range: 4.00-8.01 – Max Gain: 101%
$170 Calls – Range: 2.78-6.07 – Max Gain: 118%
_____

Fresh Ideas:
GM Weekly $36-37.50 Calls
TLRY Weekly $92.50-95 Calls  


China SXT Pharma Inc SXTC

To wrap things up we wanted to go over the call we made on Monday morning in SXTC, which at the time had registered a low of 5.684. After steadily ramping up all week, yesterday the stock reached a new high of 23.35. That worked out to an incredible four-day swing of 311%

Cheers to anyone who caught this mover in Monday morning’s premarket report. It adds to an already impressive start for us here in 2019.


Extended Watchlist:
FTK, AQMS, MGEN, NAVB, SNSS, CFRX, TEUM

Blue Horseshoe Stocks: Bottom Watchlist, Options Idea & More

Cannabis Sativa, Inc. CBDS

CBDS was part of our cannabis stock watchlist yesterday, and even as the majority of the sector was seen to be fading, CBDS bucked the trend and produced an excellent intraday opportunity.

We watched as the stock took off like a rocket right at the opening bell from a low of 1.26, and didn’t stop until hitting its 2.45 high-of-day shortly before 11′clock. That works out to a 94% swing and it came on immense volume, to the tune of 23X the 3-month average.

Cheers go out to any of our readers who caught a piece of the action on CBDS, which was the first in a trio of selections from yesterday’s premarket report to produce respectable intraday performances.


Cardinal Resources, Inc. CDNL

Next in line was CDNL, which is a stock that we’ve referenced in our reports on numerous occasions over the past several months. This subpenny runner turned in an intraday rip of 77% as it ran from .0047-.0083 on a little more than twice the average trading volume, and managed to hold the majority of its daily advance into the close at .0074.

It marked the second consecutive big day for the stock trending off of its lowest prices in roughly six months, so we’ll certainly want to continue tracking its activity, watching for it to record higher highs and higher lows in coming sessions.


Celator Pharmaceuticals, Inc. CPXX

We caught CPXX yesterday on the heels of an attention-grabbing PR (link below) which hit wires post-market on Monday afternoon, relating to encouraging results from a late-stage clinical trial. Despite already being up close to 300%, we still felt it warranted a tag in our watchlist, and we weren’t disappointed.

As is often the case in such circumstances, we saw a dip-and-rip unfold early, after which time the stock ran from a low of 6.44 to 9.10, for a solid 41% swing on absolutely massive volume.


Bottom-Watchlist

We’re going to designate the following stocks as bottom-watch plays and reserve a spot on our watchlist for each of them over the next several sessions:

Pernix Therapeutics Holdings, Inc.  PTX
Sunesis Pharmaceuticals, Inc  SNSS
Peak Resorts, Inc.  SKIS
Quantum Fuel Systems Technologies Worldwide Inc.  QTWW


Chipotle Mexican Grill, Inc. CMG -  Options Idea

We want to throw in a quick options idea this morning as well, and it’s going to come in the form of a short. Specifically, we’re going to be looking at the CMG Weekly $485-475 Puts.


Extended Watchlist:
VPRO, UPL, PSG, SIPC, LEAS, POTG

Blue Horseshoe Stocks: NUGN on Bottom-Watch & More

NuGene International, Inc. NUGN

We’re mentioning NUGN for the first time this morning on the heels of some interesting events that have recently unfolded. The stock had been on a sustained uptrend for over two months that was apparently the product of a massive promotion (in which we played no role) which resulted in the PPS running from below $2 to more than $4.

On Wednesday, the company issued a public statement to clarify that it was not involved in promotional activities of any sort >>Read PR

What followed yesterday was a massive sell-off to the tune of nearly 40%, and that’s where we enter the picture. Regardless of the catalysts behind NUGN’s gradual rise and rapid fall, we’re only interested in the chart activity that will follow. We’re going to highlight NUGN as a bottom-watch play, because the resultant bounce when the stock finds a solid level of support could make quick-strike gains a snap for those paying close enough attention.


Fresh News Plays

We’re going to tag both of the following for observation today after each published notable premarket PR’s this morning:

AmeriMex International, Inc. AMMX

In addition to announcing the latest in a long string of recently secured purchase agreements (links below), the AMMX chart is looking rather bullish at the moment.

_______

Corbus Pharmaceuticals Holdings, Inc. CRBP

We’ll also keep an eye on CRBP, which has some FDA-related news out today.

Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma) (Fri 8:12AM EDT)


Options Idea:

Twitter, Inc. TWTR is responding well in the wake of the revelation that its current CEO will be stepping down on July 1st. We’re going to put TWTR Weekly $36-38 Calls on watch today as well, for potential daytrading opportunities.


Extended Watchlist:
SNSS, OCLS, ESI, OSUR

Blue Horseshoe Stocks: NQ Review & More

NQ Mobile, Inc.  NQ

Our coverage of NQ stretches all the way back to the Fall of 2013 when the stock made a huge run, and we tracked it to a similar albeit smaller-scale spike in October, so we are quite familiar with this play. We have good reason to re-assess NQ this morning in the wake of an interesting PR, coupled with a good positioning of the chart.

In terms of the NQ chart, there a couple of finer points that we’ll point out on the following snapshot:

This morning’s PR relates to a big open market stock repurchase by management which seems to be fueling NQ in the premarket. >>> VIEW PR  



Cannabis Coverage:

A few of the marijuana-related stocks we were mentioning yesterday morning managed to put up some solid numbers over the course of the day.

CBIS traded in a range from .068-.08 (+17%) on roughly 4X its monthly average volume.

MCIG did slightly better as recorded a 19% move from .15 to .178, trading more than twice its average volume.

EAPH
also had a heavy volume day to the tune of roughly 3X its average, and made a healthy jump of 21% as it traded from its open at .024 to a high of .029.

As medical and recreational marijuana acceptance continues to spread, we’ll need to keep a close eye on these and many other cannabis plays, as we tend to believe that growth in this arena will be more substantial in 2015 than any previous year.

A few other pot plays to watch this week: WDHR, NRTI, MDCN, LATF, VPOR


Extended Watchlist:
CYTR, NERV, FRO, CPST, DARA, MNK, SNSS, RNN

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR


FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR


Extended Watchlist:
 CYRN, SYMX, SNSS